Michael Nedelcovych
Stock Analyst at TD Cowen
(0.88)
# 4,023
Out of 4,659 analysts
89
Total ratings
47%
Success rate
-2.3%
Average return
Main Sectors:
Stocks Rated by Michael Nedelcovych
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintained: Buy | $50 → $65 | $59.69 | +8.90% | 10 | Jul 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $34.25 | +16.79% | 1 | Jul 6, 2026 | |
| NVO Novo Nordisk | Maintained: Hold | $42 | $45.71 | -8.12% | 31 | Jun 29, 2026 | |
| TAK Takeda Pharmaceutical Company | Maintained: Buy | $21 | $18.05 | +16.34% | 14 | Jun 4, 2026 | |
| JNJ Johnson & Johnson | Maintained: Buy | $250 | $271.11 | -7.79% | 2 | May 29, 2026 | |
| CHRS Coherus Oncology | Maintained: Buy | n/a | $1.34 | - | 13 | May 28, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Maintained: Hold | $9.71 | $9.65 | +0.63% | 9 | Apr 30, 2026 | |
| SWX: MOLN Molecular Partners AG | Maintained: Buy | CHF 15.00 | CHF 3.46 | +333.53% | 6 | Mar 16, 2026 | |
| TYO: 4502 Takeda Pharmaceutical Company Limited | Maintained: Buy | ¥5,135 | ¥5,754 | n/a | 1 | May 21, 2025 | |
| MOLN Molecular Partners AG | Maintained: Buy | $17 | $4.29 | n/a | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | ¥6,550 | ¥2,729 | n/a | 1 | Sep 9, 2024 |
Royalty Pharma
Jul 13, 2026
Maintained: Buy
Price Target: $50 → $65
Current: $59.69
Upside: +8.90%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $34.25
Upside: +16.79%
Novo Nordisk
Jun 29, 2026
Maintained: Hold
Price Target: $42
Current: $45.71
Upside: -8.12%
Takeda Pharmaceutical Company
Jun 4, 2026
Maintained: Buy
Price Target: $21
Current: $18.05
Upside: +16.34%
Johnson & Johnson
May 29, 2026
Maintained: Buy
Price Target: $250
Current: $271.11
Upside: -7.79%
Coherus Oncology
May 28, 2026
Maintained: Buy
Price Target: n/a
Current: $1.34
Upside: -
Bausch Health Companies Inc.
Apr 30, 2026
Maintained: Hold
Price Target: $9.71
Current: $9.65
Upside: +0.63%
Molecular Partners AG
Mar 16, 2026
Maintained: Buy
Price Target: CHF 15.00
Current: CHF 3.46
Upside: +333.53%
Takeda Pharmaceutical Company Limited
May 21, 2025
Maintained: Buy
Price Target: ¥5,135
Current: ¥5,754
Upside: n/a
Molecular Partners AG
Mar 14, 2025
Maintained: Buy
Price Target: $17
Current: $4.29
Upside: n/a
Sep 9, 2024
Maintained: Buy
Price Target: ¥6,550
Current: ¥2,729
Upside: n/a